Nisar Ahmad, MD
Hematology · Harlingen, TXNPI 1659390045
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $83 of the $98 with a category attached, or 84.7%. 4 manufacturers reported payments, led by Daiichi Sankyo Inc. at 47.1% of the total. Reporting peaked in 2021 at $46 and has fallen 54.0% since, to $21 in 2023. That places this record below the midpoint for hematology clinicians in TX, where the typical reported total is $822.
Across 5 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$46
- Philips North America LLC$21
- Sebela Pharmaceuticals Inc.$16
- E.r. Squibb & Sons, L.L.C.$15
Across 3 payments — averaging $534.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Morphosys AG$2K
What the payments were for
- Food & beverage$8385%
- Education$1515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 2 | $46 |
| Philips North America LLC | 1 | $21 |
| Sebela Pharmaceuticals Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
How this compares
$98 in reported general payments places this provider in the 20th percentile of 97 hematology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 25 | $323,705 |
| XtandiEnzalutamide | 20 | $237,437 |
| IbrancePalbociclib | 17 | $230,996 |
| ImbruvicaIbrutinib | 14 | $205,021 |
| Abiraterone Acetate | 11 | $98,341 |
| Imatinib Mesylate | 17 | $52,522 |
| OrgovyxRelugolix | 20 | $52,359 |
| XareltoRivaroxaban | 18 | $12,209 |
| EliquisApixaban | 14 | $11,339 |
| PradaxaDabigatran Etexilate Mesylate | 14 | $3,045 |
| Anastrozole | 93 | $2,481 |
| Exemestane | 14 | $1,478 |
| Tamoxifen Citrate | 39 | $1,169 |
| Hydroxyurea | 41 | $908 |
| Alendronate Sodium | 33 | $717 |
Paid to pharmacies, not to this prescriber.
Other hematology in Harlingen
- Miguel EscobarHouston$767K
- Kelty BakerHouston$229K
- Siddhartha GangulyHouston$119K
- Lawrence RiceHouston$103K
- Modupe IdowuHouston$102K
- Taha BatDallas$81K
- Montaser ShaheenSan Antonio$75K
- Swaminathan IyerHouston$50K
- Roger LyonsSan Antonio$44K
- Ankit KansagraDallas$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.